益生元果寡糖对非透析慢性肾脏病患者尿毒症毒素的影响:一项随机对照试验
该双盲安慰剂对照随机试验纳入50例非糖尿病非透析慢性肾脏病(eGFR<45 mL/min/1.73 m²)患者,随机接受果寡糖(FOS)12 g/天或安慰剂12 g/天治疗3个月。主要结局为血清总/游离对甲酚硫酸盐(PCS)变化,组间差异呈趋势但未达统计学显著(P=0.07),其他毒素及次要结局无差异。提示FOS可能降低血清总及游离PCS。
要点
- FOS 12 g/天治疗3个月对血清总PCS变化的影响呈边缘趋势(P=0.07),未达显著。
- FOS对尿PCS、IS、IAA及其他次要结局无显著影响。
- FOS组高密度脂蛋白胆固醇下降,其余安全性指标无差异。
核心结论
- 果寡糖可能降低非糖尿病非透析慢性肾脏病患者的血清总及游离对甲酚硫酸盐水平。
研究设计与样本
- 双盲、安慰剂对照、随机试验,为期3个月。
- 纳入50例非糖尿病非透析慢性肾脏病患者,估算肾小球滤过率<45 mL/min/1.73 m²,年龄18-80岁。
- 干预组接受果寡糖12 g/天,对照组接受麦芽糊精12 g/天。
- 46例完成随访。
主要发现
- 血清总PCS变化组间差异呈趋势:治疗效应(校正基线水平)-12.4 mg/L,95% CI -5.6至0.9 mg/L,P=0.07。
- 血清游离PCS变化百分比组间差异呈趋势:干预组-8.6%(-41.5至13.9%),安慰剂组3.5%(-28.8至85.5%),P=0.07。
- 血清总PCS变化的趋势独立于eGFR和膳食蛋白:纤维比值摄入。
- 尿PCS、IS、IAA及其他次要结局组间无差异。
- 干预组高密度脂蛋白胆固醇下降,其余指标无差异。
临床怎么用
- 对于非糖尿病非透析慢性肾脏病患者,果寡糖可能作为调节尿毒症毒素的潜在干预手段,但当前证据未达统计学显著,需进一步验证。
局限性
- 样本量较小(50例随机,46例完成),主要结局仅为趋势。
- 研究人群限于非糖尿病非透析慢性肾脏病患者,外推性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Microbial-derived uremic toxins, p-cresyl sulfate (PCS), indoxyl sulfate (IS) and indole 3-acetic acid (IAA), have been associated with the burden of chronic kidney disease (CKD). Prebiotics have emerged as an alternative to modulate the gut environment and to attenuate toxin production. This trial aims to investigate the effect of a prebiotic fructooligosaccharide (FOS) on uremic toxins of non-dialysis-dependent CKD (NDD-CKD) patients. METHODS: A double-blind, placebo-controlled, randomized trial was conducted for 3 months. In all, 50 nondiabetic NDD-CKD patients [estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2], aged 18-80 years, were allocated to prebiotic (FOS, 12 g/day) or placebo (maltodextrin, 12 g/day) groups. Primary outcomes were changes in serum (total and free) and urinary (total) PCS. Secondary outcomes included changes in IS, IAA, serum markers of intestinal permeability (zonulin), gut-trophic factors (epidermal growth factor and glucagon-like peptide-2), eGFR, inflammation (high sensitive c-reactive protein and interleukin-6), homeostatic model assessment-insulin resistance, lipid profile and gastrointestinal symptoms. RESULTS: From 50 participants (54% men, 57.3 ± 14.6 years and eGFR 21.4 ± 7.6 mL/min/1.73 m2), 46 completed the follow-up. No changes in dietary intake or gastrointestinal symptoms were observed. There was a trend in the difference of serum total ΔPCS (treatment effect adjusted for baseline levels: -12.4 mg/L; 95% confidence interval (-5.6 to 0.9 mg/L; P = 0.07) and serum-free Δ%PCS [intervention -8.6 (-41.5 to 13.9%) versus placebo 3.5 (-28.8 to 85.5%); P = 0.07] between the groups. The trend in the difference of serum total ΔPCS was independent of eGFR and dietary protein:fiber ratio intake. No difference was found in urinary PCS. Aside from the decreased high-density lipoprotein cholesterol in the intervention, no differences were observed in the change of IS, IAA or other secondary outcome between the groups. CONCLUSIONS: Our result suggests the potential of FOS in reducing serum total and free PCS in nondiabetic NDD-CKD patients.
引用
- Ramos CI, Armani RG, Canziani MEF, et al. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant. 2019. PMID: 29939302. doi:10.1093/ndt/gfy171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。